RxDoctor Payments Data

Dalton Carter, MD

Family Medicine · Houston, TXNPI 1124656715

Payments from drug & device makers

$2,386in general payments, 2019–2025

Across 100 payments — averaging $23.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$458
  • Lilly USA, LLC$356
  • Pfizer$256
  • AbbVie$246
  • GSK$174
  • AstraZeneca$172
  • plus $725 from 12 others

What the payments were for

  • Food & beverage$2,386100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,386 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$19,632
Medicare patients
71
Services billed
240

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide23$28,461
MounjaroTirzepatide16$24,848
FarxigaDapagliflozin Propanediol14$16,281
Telmisartan-HydrochlorothiazidTelmisartan/Hydrochlorothiazid26$1,606
Azelastine Hcl47$959
Atorvastatin Calcium62$729
Albuterol Sulfate HfaAlbuterol Sulfate33$542
Rosuvastatin Calcium47$464
Fluticasone Propionate50$420
Gabapentin26$385
Potassium Chloride15$378
Duloxetine Hcl14$378
Amlodipine Besylate38$300
Tizanidine Hcl29$281
Tamsulosin Hcl20$271

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$458$28,46123 claims
Lilly USA, LLCMounjaro$356$24,84816 claims
AstraZenecaFarxiga$172$16,28114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →